SunBio
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
SunBio develops and supplies PEG (polyethylene glycol) derivatives, chemical building blocks used to make biopharmaceutical drugs, and has its own drug products, including a treatment for a condition called neutropenia (a dangerous drop in white blood cells caused by chemotherapy) and a dry-mouth therapy.
Its neutropenia drug is supplied to Intas Pharma, which manufactures the finished product for markets including the EU, Canada, Australia, and India, with SunBio earning royalties on those sales. Listed on KOSDAQ, Korea's tech-focused small-cap board, the company's core revenue engine is its PEG-derivative supply and royalty business, while it also runs early-stage research into artificial blood and solid-state battery electrolytes.
Summary is AI-generated and may contain errors · figures from DART filings
SunBio's PEG-derivative and drug businesses are built on its proprietary pegylation technology platform, which it is also applying to new areas such as lipid nanoparticle stabilization and battery electrolytes.
SunBio in five facts
What does SunBio do?
SunBio develops and supplies PEG (polyethylene glycol) derivatives, chemical building blocks used to make biopharmaceutical drugs, and has its own drug products, including a treatment for a condition called neutropenia (a dangerous drop in white blood cells caused by chemotherapy) and a dry-mouth therapy.
Where is SunBio listed and in which sector?
SunBio (Korean name: 선바이오) trades under KRX code 067370 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is SunBio?
Its market capitalisation was US$53.9M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were SunBio's latest annual revenue and operating profit?
For fiscal year 2025, SunBio reported revenue of US$10.3M, operating profit of US$3.8M and net income of US$2.1M, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was up 57.5% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Early redemption of convertible bonds (incl. overseas CBs)Capital raise · Sep 7
- Change of 30% or more in revenue or profit/loss structure (15% for large companies)
SunBio reported separate results for FY2025: revenue of US$9.35M (+57.47% year on year), operating profit of US$3.44M (from a loss a year earlier) and net income of US$1.87M (from a loss a year earlier).
Earnings · Feb 9